Kornimate/medical-research-clean huggingface dataset:
observational trial of qigong for patients in pain

Conditions: Chronic Pain

Summary: this observational study documented outcomes resulting from qigong practice as a complementary self-care practice. all subjects continued with their usual medical care. recruitment was passive, and participants consisted of those who encountered the practice as part of an earlier clinical trial, or entered the program prior to the observational period (posted information, word-of-mouth), or entered during the observational period (posted information).


Eligibility criteria:
inclusion criteria: * those undertaking qigong practice as a complementary self-care practice at the pain management unit exclusion criteria: * none
cellular and molecular adaptations to exercise-induced inflammatory response in children with autoimmune diseases

Conditions: Juvenile Idiopathic Arthritis

Summary: juvenile idiopathic arthritis (jia) is a chronic disease characterized by persistent joint inflammation. the immune system disruption that leads to overproduction of pro-inflammatory cytokines (tnf-α, il-1, il-6) is a cascade of events on different levels-some molecular, some cellular, and some systemic. our objective is to identify the mechanisms through which physical activity is liable to mediate inflammatory balance in autoimmune disease settings, and specifically in jia patients.

feasibility study

Eligibility criteria:
inclusion criteria: * children between 8 and 12 years * tanner stage \< t2 * polyarthritis, oligoarthritis and era sub-type of jia * stable disease during 3 months before starting study exclusion criteria: * infection * fever * anti-il6 treatment * more than 6h per week of physical activity * systemic corticosteroid treatment during the 3 months before starting study * systemic jia * jia not mastered by treatments * other autoimmunity or auto-inflammatory diseases * participation in another clinical research protocol

Keywords: juvenile idiopathic arthritis physical exercise pro-anti-inflammatory balance interleukins mirna calgranulins
the effect of the self-care support program on women with endometriosis

Conditions: Endometriosis; Quality of Life; Depression; Anxiety; Stress

Summary: this study, was aimed to evaluate the effect of self-care support program (self-care training in endometriosis + motivational interview) applied to women with endometriosis on quality of life, self-care behaviors, depression, anxiety and stress levels.

this study is a randomized controlled experimental study conducted to evaluate the effect of self-care support program applied to women with endometriosis on quality of life, self-care behaviors, depression, anxiety and stress levels.the research was carried out with the participation of two groups. endometriosis self-care support program-essp (intervention group) will be applied to one of the groups, while the other group (control group) will receive standard treatment within the scope of the hospital protocol. then, women's quality of life, self-care behaviors, depression, anxiety and stress levels will be evaluated.

Eligibility criteria:
inclusion criteria: * reproductive age (between 18-49 years old), * diagnosed with endometriosis (symptomatic patients), * having no medical or gynecological problems other than endometriosis, * literate, * mobile phone user, * non-pregnant, * no communication barrier * not diagnosed with a psychiatric illness, * who volunteered to participate in the research, * women who can speak and understand turkish will be included. exclusion criteria: * who could not attend any session of essp (only in the intervention group), * filling the data collection forms incompletely, * pregnant at the time of the study and * women who have been hospitalized and/or had surgical operations for gynecological and medical reasons will be excluded.

Keywords: endometriosis self-care support program quality of life motivational interview self-care behaviors
pringle's maneuver versus selective hepatic vascular exclusion in hepatectomy

Conditions: Hepatocellular Carcinoma

Summary: to confirm that shve is a safe and effective procedure and it can prevent bleeding of the hepatic vein. to evaluate the recurrence and metastasis in hcc patients undergoing hepatectomy by shve.to evaluate that shve can improve survival in hcc patients or not.

hepatocellular carcinoma (hcc), a serious disease with high incidence at home and abroad still shows a rising trend. in recent decade, the overall survival rate of the disease has entered a platform stage with little advance despite diversified methods of treatment. the prognosis of hcc is not so satisfying. intraoperative bleeding remains a major concern during liver resection. blood loss usually occurs during parenchymal transection and reperfusion after pringle's maneuver. the amount of blood loss and the need for blood transfusion have a detrimental effect on the short- and long-term prognosis. portal triad clamping is sufficient in most situations to control bleeding during hepatectomy. however, it does not prevent backflow bleeding from hepatic veins, which may become troublesome or even hazardous. this is particularly true in tumors that are large or that have invaded into the branches of the major hepatic veins. shve completely isolates the liver from the systemic circulation with the advantage of preventing backflow hemorrhage or air embolism without having to resort to caval blood flow interruption of thve. the purpose of the study is to assess the risk factors for the recurrence and metastasis in hcc patients undergoing hepatectomy by shve and to evaluate that shve can improve survival in hcc patients or not.

Eligibility criteria:
inclusion criteria: * corresponding to diagnostic standards of hcc. * patients of liver tumors underwent resection with occlusion of more than one main hepatic veins. * liver function in the child-pugh classification a or b. * age between 18\~70 years. * haven't taken any current treatment. * understanding and being willing to sigh the informed consent form. exclusion criteria: * cannot be follow-up * severe liver, renal, or brain dysfunction * with tumor thrombi in the main trunk of portal vein * with tumor thrombi in the hepatic vein * with extrahepatic metastasis

Keywords: hepatocellular carcinoma hepatic vein surgical resection occlusion time to recurrence overall survival
clinical trial for oral formula of vanillin and wheat germ oil for treatment of mild and moderate covid-19 viral disease

Conditions: Mild-to-moderate COVID-19

Summary: * the study is a randomized clinical trial to assess a natural formula of vanillin \& wheat germ oil to treat and stop the clinical progression of covid-19. * the study aims to treat people with mild-to-moderate covid-19 before their cases become severe. * the study duration is a 5-day experimental intervention and an extended 4 weeks follow up.


Eligibility criteria:
inclusion criteria: 1. pcr confirmed diagnosis for covid-19. 2. age ≥18 years. 3. both genders 4. the disease started within 7 days (ideally 72 hours) of diagnosis or clinical deterioration. 5. patients diagnosed as mild or moderate exclusion criteria: 1. patients diagnosed with severe illness: individuals who have spo2 \ 30 breaths/min, or lung infiltrates \>50%. 2. general: advanced kidney disease; advanced liver disease; pregnancy (known or potential) or lactation, and advanced cardiovascular diseases. 3. allergy to vanilla flavor, vanillin, or wheat germ oil 4. active cancer

Keywords: mild-to-moderate covid-19 vanillin, wheat germ oil
study evaluating the safety and efficacy of enbrel (etanercept) in japan

Conditions: Rheumatoid Arthritis

Summary: the special use-results surveillance is conducted in patients who have never been treated with enbrel and in whom its long-term therapy may be instituted in the actual setting of use after marketing with the following objectives: 1. to examine the safety of long-term use of enbrel including the occurrence of malignant tumors. 2. to confirm the efficacy of enbrel in the long-term use.


Eligibility criteria:
inclusion criteria: inclusion criteria patients with rheumatoid arthritis (ra) who fulfill all of the following 1. patients who are refractory to the treatment. 2. patients who have never been treated with enbrel and in whom its long-term therapy may be instituted. 3. patients without a history of or concurrent malignant tumors. exclusion criteria:
effect of gaba on adhd and seizures in children with epilepsy.

Conditions: Epilepsy

Summary: effect of gaba on adhd and seizures in children with epilepsy.

effect of gamma aminobutyric acid on adhd and seizures in children with epilepsy.

Eligibility criteria:
inclusion criteria: * epilepsy * adhd exclusion criteria: * epilepsy without adhd
efficacy of postural restriction in treating benign paroxysmal positional vertigo

Conditions: Benign Paroxysmal Positional Vertigo

Summary: the standard treatment of posterior semicircular canal benign paroxysmal positional vertigo is the canalith repositioning procedure or the epley maneuver. based on the present literature, there is controversy on the efficacy of post-maneuver postural restrictions.the aim of this study was to conduct a randomized controlled trial to compare the treatment efficacy of post-maneuver postural restriction with crp alone in patients with posterior semicircular canal benign paroxysmal positional vertigo.

benign paroxysmal positional vertigo is the most common cause of vertigo. based on the present literature, there is controversy on the efficacy of post-maneuver postural restrictions.some study designs were not randomized controlled trials. the present study offers an alternative way of postural restriction to maintain postural restriction as much as possible.

Eligibility criteria:
inclusion criteria: * patients with unilateral posterior semicircular canal benign paroxysmal positional vertigo and * a negative neurologic examination exclusion criteria: * secondary benign paroxysmal positional vertigo caused by trauma head injury, inner ear surgery, viral labyrinthitis or meniere's disease * patients with central vertigo, cervical spine, neurologic, otologic, psychiatric diseases * patients who used medications that affected the neurologic and otologic systems for less than 48 hours

Keywords: benign paroxysmal positional vertigo, postural restriction
biomarkers in thoracic aorta surgery

Conditions: Aortic Aneurysm; Thoracoabdominal Aneurysm; Aortic Dissection; Complication

Summary: biomarkers can play a vital role in prognosing the perioperative complications in thoracic aorta surgery. the goal of a study is to determine the correlation between intraoperative level of certain biomarkers and total amount of peroperative complications.

this study aims to assess the association between levels of biomarkers and postoperative complications in patients after thoracic and thoracoabdominal aortic reconstruction.

Eligibility criteria:
inclusion criteria: * elective thoracic and thoracoabdominal surgery exclusion criteria: * hemolysis in blood sample
treatment using 448 khz crmrf in subacromial syndrome.

Conditions: Shoulder Impingement Syndrome; Subacromial Impingement Syndrome

Summary: the purpose of this study is to assess the effectiveness of 448 khz capacitive resistive monopolar radiofrequency in the treatment of subacromial syndrome.

shoulder pain has a high prevalence in our society, several studies estimate an annual prevalence between 5% and 47%. it is one of the main causes of musculoskeletal pain, particularly in third place, after the low back pain and neck pain. symptoms of pathologies of subacromial syndrome, where, regardless of origin, pain is the number one symptom for the patient, which emanates functional impairment and the impact on quality of life. among the non-pharmacological treatments of subacromial syndrome, a systematic review concludes that the first line of intervention should be a therapeutic exercise program. in many cases, this is usually accompanied by the application of electrophysical agents (short wave, laser, etc.). a recent study has shown that the application of short wave radio frequency improved pain in people with subacromial syndrome. the current frequency that is applied in the short wave is 27.12 mhz, however, there are other relatively new forms of radiofrequency in which a frequency less than 1 mhz is used. these are beginning to be used in clinical practice and recently have shown positive results related to pain and functionality of musculoskeletal pathologies such as knee osteoarthritis. in these two clinical trials, what is called resistive capacitive monopolar radio frequency (rfcr) was used, the frequency of which was 448 khz and 485khz respectively, much lower than the frequency used in shortwave. the rfcr has a potential advantage since it is applied with electrodes directly on the skin and is not transmitted in the air unlike the short wave. based on the few clinical trials in people with pathology and the physiological effects evidenced in healthy people and in vitro preclinical studies, it is considered pertinent to carry out the present investigation.

Eligibility criteria:
inclusion criteria: * patients between 18 and 70 years years old with diagnosis of subacromial syndrome * visual analogue scale (vas) less than or equal to 7. * positive neer and hawkins test. exclusion criteria: * clinical examination compatible with complete rotator cuff tear (drop-arm positive test) * fibromyalgia * adhesive capsulitis * be receiving physiotherapeutic treatment or have received it previously for this pathology one month before the start of treatment. * patients with alterations of thermal sensitivity. * derived from the absolute and relative contraindications of crmrf: * pacemaker * thrombophlebitis * pregnancy * skin disorders (recent wounds or burns)

Keywords: shoulder pain shoulder impingement syndrome radiofrequency treatment electrophysical agents
methicillin-sensitive and methicillin-resistant staphylococcus aureus (mssa/mrsa) - point-of-care-testing (poct) in clinical decision making

Conditions: Staphylococcus Aureus

Summary: the study epics-6 consists of three study phases. emergency department patients are screened for nasal and pharyngeal colonisation with methicillin sensitive and methicillin resistant staphylococcus aureus (mssa/mrsa) using a point-of-care (poc)-pcr-testing method (cobas®liat®-system, roche molecular systems inc.) the first aim of this study is to describe the prevalence of mssa/mrsa-colonisation in a routine cohort of emergency department patients. the second aim is to determine the impact of poc-guided decolonisation as compared to conventional laboratory testing on in-hospital infection rates with mssa/mrsa in a pre-post-comparison study.

the study epics-6 consists of three study phases. in phase one the novel poc-pcr-testing method for mssa/mrsa-proof (cobas®liat®-system, roche molecular systems inc.) is technically established and integrated in emergency department procedures. after evaluation of processes and sample handling the second phase of this study assesses the prevalence of positive mssa/mrsa-poc-testing in the general ed-population and in different risk groups. based on the results of the previous study phases, the final phase comprises an interventional pre-post-comparison study. the interventional study assesses the impact of poc-result guided early decolonisation of mssa/mrsa-colonized patients on in-hospital infection rates with mssa/mrsa.

Eligibility criteria:
inclusion criteria: * age \>= 18 years * emergency department (ed) visit in one of the participating eds exclusion criteria: * none

Keywords: staphylococcus aureus nosocomial infection decolonization emergency department
changes in the mri signal in patients with benign tumors of the brain and meninges treated with proton therapy: impact of tel and the biological dose received

Conditions: Benign Brain Tumors; Proton Therapy

Summary: the main objective is to detect with tesla multiparametric 3 mri, the mri secondary changes to protontherapy irradiation and to correlate them with tel mapping, physical dose and biological dose. a model should thus be able to be proposed at the end of the study.


Eligibility criteria:
inclusion criteria: * histologically proven or highly probable grade i meningiomas, histologically proven grade ii meningiomas. * only meningiomas of the anterior and middle floors of the base of the skull are included. * indication of proton therapy retained in rcp and / or proton therapy technical staff (caen site) * patient aged 18 or over * patient affiliated to a social security scheme * signature of informed consent before any specific procedure related to the study exclusion criteria: * history of brain or face irradiation. * implant or foreign body that can alter mri imaging. * contraindication to mri (pace maker, claustrophobia ...) - hypersensitivity to gadoteric acid, to meglumine or to any medicine containing gadolinium * genetic radio sensitizing syndrome * known neurological comorbidities (stroke, parkinson's, etc.) that may impact mri data. * simultaneous participation in a therapeutic clinical trial * patient unable to undergo the trial follow-up for geographic, social or psychopathological reasons * pregnant or breastfeeding women * persons deprived of their liberty (see article l 1121-6 csp), * adults who are the subject of a legal protection measure or unable to express their consent (see article l 1121-8)

Keywords: mri
phase 3 study of mci-186 for treatment of amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Summary: the primary objective of the study is to confirm the efficacy of 60 mg of mci-186 via intravenous drip infusion once a day in the patients with als based on the changes in the revised als functional rating scale (alsfrs-r) scores after 24 weeks administration in double-blind, placebo-controlled manner. the study is also to examine the safety of mci-186 to the als patients.


Eligibility criteria:
inclusion criteria: * patients whose conditions are defined as "definite als"or "probable als"diagnostic criteria el escorial and revised airlie house. * patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life. * patients of less than 2 years after the onset of als. * patients whose progress of the condition during 12 weeks before administration meet other requirements. exclusion criteria: * patients with such complications as parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone. * pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception. * patients who have participated in other trials within 12 weeks before consent, or who are participating in other clinical trials at present. * in addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.

Keywords: amyotrophic lateral sclerosis (als)
clinical outcomes of hbeag-negative chb patients with indeterminate phase

Conditions: Chronic Hepatitis b

Summary: chronic hepatitis b virus (hbv) infection remains a global public health burden around the world. investigating the disease process of chronic hepatitis b (chb) is essential to individual management in clinical practice. according to american association for the study of liver diseases (aasld) 2018 hepatitis b guidance, chb can be classified into four phases: immune-tolerant chb, hbeag-positive immune active chb, inactive chb and hepatitis b e antigen (hbeag)-negative immune active chb. antiviral therapy is recommended in patients with hbeag-positive or -negative immune active chb patients to reduce the incidence of liver cirrhosis and hepatocellular carcinoma, while periodic monitoring is recommended for inactive carrier and immune-tolerant chb patients. however, a substantial proportion of patients fall into an indeterminate phase whose serum hbv dna and alanine aminotransferase levels do not fit well into these well-described phases. most of chb patients with indeterminate phase are hbeag negative. however, the clinical outcomes of these patients remain unclear. therefore, the purpose of this study is to investigate the clinical outcomes of hbeag-negative chronic hepatitis b patients with indeterminate phase.


Eligibility criteria:
inclusion criteria: 1. hepatitis b surface antigen (hbsag) positive over 6 months 2. age ≥18 years 3. treatment-naïve 4. hbeag negative, anti-hbe positive 5. hbv dna \>2000 iu/ml 6. persistently normal alanine transaminase (alt) 7. liver inflammation \ 8 kilopascals (kpa) 8. no family history of liver cirrhosis or hepatocellular carcinoma exclusion criteria: 1. coinfection with hepatitis a virus, hepatitis c virus, hepatitis d virus, hepatitis e virus or human immunodeficiency virus; 2. coexisting of hepatocellular carcinoma and other malignancy, or alpha-fetoprotein \>upper limit of normal at enrollment; 3. presence of liver cirrhosis; 4. alcohol abuse within the last year (ethanol: male \>40 g/d, female \>20 g/d; or heavy drinking within 2 weeks before enrollment: ethanol \>80 g/d), or history of drug abuse; 5. participating in other clinical trials in the last 3 months; 6. coexisting of autoimmune liver diseases; 7. pregnant or planned pregnancy in a short term or lactation patients; 8. history of severe heart disease, mental disease; 9. uncontrolled diabetes, hypertension, thyroid dysfunction, retinopathy, autoimmune diseases; 10. neutrophil count \<2×10\^9/l and/or platelet count \<100×10\^9/l; 11. history of organ transplantation or preparing for organ transplantation; 12. using immunosuppressive drugs; 13. undergone organ transplantation or preparing for organ transplantation; 14. receiving immunosuppressive agents; 15. patients thought by the investigators not suitable to participate in this study.

Keywords: chronic hepatitis b indeterminate phase hepatitis b surface antigen clearance hepatocellular carcinoma antiviral treatment
a web-and mobile phone-based intervention in 4-year-olds: a population-based randomized controlled trial

Conditions: Obesity

Summary: this study aims to evaluate the effects of a mobile phone-based dietary and physical activity intervention on body fatness, dietary intake and physical activity of preschoolers

childhood overweight and obesity is an increasing health problem globally, and can be established as early as 2-5 years of age. mobile phone based (mhealth) interventions have been successful for weight management in adults; however, their potential in young children is yet to be established. therefore, the ultimate goal of ministop (mobile-based intervention intended to stop obesity in preschoolers) trial is to help parents of four year old children to achieve a healthy weight and body fat via a smartphone app (ministop). more specifically this trial aims to reduce body fat (primary outcome), increase the intake of fruits, vegetables as well as decrease the intake of candy, and sweetened beverages, and increase the amount of time spent in moderate-to-vigorous physical activity and decrease sedentary behaviors (secondary outcomes) in healthy preschool aged swedish children. if the ministop app is effective, it has the potential to be incorporated into the child health care to aid in counteracting overweight and obesity.

Eligibility criteria:
inclusion criteria: * parents having a four year old child and living in östergötland; having the ability to have their child measured at baseline at 4.5 years ± 2 months of age * at least one parent had to able to speak and read swedish sufficiently well (i.e. be able to provide informed consent and understand the intervention content) exclusion criteria: * a child with a neurological or endocrine disease effecting weight * a child with a parent suffering from a serious physical or psychological disease making the study too demanding for the family.